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Background:While most recent evidence does not support a role for
pregnancy in accelerating HIV disease progression, very little infor-
mation is available on the effects of incident pregnancy in response to
antiretroviral therapy (ART). Hormonal, immune, and behavioral
changes during pregnancy may inﬂuence response to ART. We sought
to explore the effects of incident pregnancy (after ART initiation) on
virologic, immunologic, and clinical response to ART.
Methods: Data were collected from HIV-infected women partici-
pating in 3 prospective studies (Partners in Prevention Herpes simplex
virus/HIV Transmission Study, Couples Observational Study, and
Partners Preexposure Prophylaxis Study) from 7 countries in Africa
from 2004 to 2012. Women were included in this analysis if they were
#45 years of age, were started on ART during the study and were not
pregnant at ART initiation. Pregnancy was treated as a time-dependent
exposure variable covering the duration of pregnancy, including all
pregnancies occurring after ART initiation. Virologic failure was
deﬁned as a viral load (VL) greater than 400 copies per milliliter $6
months after ART initiation and viral suppression was deﬁned as
VL#400 copies per milliliter. Multivariable Cox proportional hazards
models were used to assess the association between pregnancy and
time to viral suppression, virologic failure, World Health Organization
clinical stage III/IV, and death. Linear mixed-effects models were used
to assess the association between pregnancy and CD4+ count and VL.
All analyses were adjusted for confounders, including pre-ART CD4+
count and plasma VL.
Results: A total of 1041 women were followed, contributing 1196.1
person-years of follow-up. Median CD4+ count before ART initiation
was 276 cells per cubic millimeter (interquartile range, 209–375);
median pre-ART VL was 17,511 copies per milliliter (interquartile
range, 2480–69,286). One hundred ten women became pregnant after
ART initiation. Pregnancy was not associated with time to viral
suppression (adjusted hazard ratio [aHR], 1.20, 95% conﬁdence
interval [CI]: 0.82 to 1.77), time to virologic failure (aHR, 0.67,
95% CI: 0.37 to 1.22), time to World Health Organization clinical stage
III or IV (aHR, 0.79, 95% CI: 0.19 to 3.30), or time to death (aHR,
2.04, 95% CI: 0.25 to 16.8). Incident pregnancy was associated with an
adjusted mean decrease in CD4+ T-cell count of 47.3 cells per cubic
millimeter (P , 0.001), but not with difference in VL (P = 0.06).
Conclusions: For HIV-infected women on ART, incident preg-
nancy does not affect virologic control or clinical HIV disease
progression. A modest decrease in CD4+ T-cell count could be due
to physiologic effects of pregnancy.
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The question of whether pregnancy inﬂuences HIV type 1disease progression has been the subject of several
investigations.1–15 However, very limited information is
available on the effects of pregnancy in response to anti-
retroviral therapy (ART). There are several mechanisms by
which pregnancy may affect response to ART, both biologic
and behavioral, that can affect drug intake and adherence.
Pregnancy related physiological changes may affect absorp-
tion, distribution, metabolism, or excretion of drugs.16
Pregnancy may also alter immune responses.17
Information on potential effects of incident pregnancy
in response to ART is particularly relevant for resource-
limited settings, as plans for ART rollout among all
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HIV-infected women of reproductive age are currently in
progress in many such countries. The few studies addressing
this question from sub-Saharan African settings have led to
differing conclusions of either no change in risk or of increased
risk of virologic failure on ART with pregnancy.18–21 Studying
the effects of pregnancy in response to ART has, nonetheless,
great importance for policy, particularly with regards to
counseling HIV-infected women who are on ART about their
fertility desires and subsequent family planning or optimizing
prepregnancy health.
We examined whether pregnancy affects response to
ART among HIV-infected women followed in 3 prospective
studies of HIV-serodiscordant couples in Africa.
METHODS
Study Population
Enrollment and follow-up for the Partners in Prevention
Herpes simplex virus (HSV)/HIV Transmission Study (2004–
2008), the Couples Observational Study (2008–2010), and the
Partners Preexposure Prophylaxis (PrEP) Study (2008–2013)
has been previously described.22–27 Brieﬂy, HIV-serodiscordant
heterosexual couples from 7 African countries (Botswana,
Kenya, Rwanda, South Africa, Tanzania, Uganda, and Zambia)
were enrolled and followed between 2004 and 2013. Overall in
63% of couples, the HIV-infected partner was female. At the
time of enrollment, HIV-infected partners did not meet national
guideline eligibility criteria for ART use; during follow-up,
clinical and immunologic status was monitored and ART was
recommended and initiated according to national guidelines.
Demographic information was collected at enrollment,
whereas data on ART use were collected quarterly with
follow-up continuing for a maximum of 1 year (Couples
Observational Study), 2 years (Partners in Prevention HSV/
HIV Transmission Study), or 3 years (Partners PrEP Study).
CD4+ T-cell counts were measured every 6 months; HIV viral
load (VL) was measured every 6 months in the Partners in
Prevention Study and Couples Observational Study and
annually in the Partners PrEP Study. Pregnancy status was
ascertained at each study visit by history; urine pregnancy
tests were performed quarterly in the Partners in Prevention
HSV/HIV Transmission Study and as clinically indicated in
the other 2 studies. Date of last menstrual period (LMP),
estimated date of delivery, and pregnancy information were
collected with standardized questionnaires. All women gave
written informed consent. The studies were approved by the
University of Washington Human Subjects Review Commit-
tee and local ethic review boards at each study site.
Statistical Analysis
For this analysis, women were included if they (1) were
enrolled as the HIV-infected partner in the HIV-serodiscordant
couple, (2) were started on ART during study follow-up, (3)
were not pregnant at the time of ART initiation, (4) were aged
45 years or younger, and (5) had at least one study visit at which
plasma was obtained for HIV VL assessment after starting ART
(N = 1041). Pregnancies prevalent at the time of ART initiation
were excluded, as many pregnant women are started on ART to
prevent mother-to-child transmission of HIV, and not for their
own clinical indications. The exposure was pregnancy occurring
after ART initiation, deﬁned as a time-dependent variable, which
could include multiple pregnancies occurring after ART initia-
tion. Start of pregnancy was deﬁned as the date of LMP and the
end of pregnancy as the date of delivery or pregnancy loss.
Complete data on LMP and date of delivery were available for
96% of pregnancies; for the remaining pregnancies, start and end
dates were estimated using the reported duration of the
pregnancy based on maternal history and either the LMP or
date of delivery. Virologic failure was deﬁned as plasma HIV
RNA greater than 400 copies per milliliter 6 months or later after
ART initiation. This included both failure to achieve virologic
suppression within 6 months of initiating ART and virologic
rebound after initial suppression. To meet this outcome, women
had to have at least one plasma HIV VL result 6 months or later
after ART initiation (n = 769).
We compared baseline characteristics between women
who became pregnant after ART initiation and those who did
not using Wilcoxon rank-sum tests or x2 tests. Multivariable
Cox proportional hazards models stratiﬁed by study and
extended Kaplan–Meier curves28 were used to assess the
effect of incident pregnancy after ART initiation on time to
virologic suppression (HIV VL#400 copies per milliliter), time
to virologic failure, time to World Health Organization (WHO)
clinical stage III or IV, and time to death. Linear mixed-effects
models were used to assess the effect of time-varying incident
pregnancy on CD4+ T-cell count and plasma HIV VL after ART
initiation. Age, study year, education, income, marital status,
parity, CD4+ T-cell count before ART initiation, HIV VL before
ART initiation, and diagnosis of tuberculosis at ART initiation
were considered as potential confounders, and were included in
ﬁnal models if the hazard ratio for incident pregnancy changed
by greater than 10%. All analyses were conducted in SAS 9.3
(SAS Institute, Cary, NC).
RESULTS
Participant Characteristics
Among the 1041 women included in this analysis, most
(81.2%) were enrolled in the Partners PrEP Study. The great
majority (95.7%) were married, whereas about half reported
any monthly income (Table 1). Their median age was 32 years,
median duration of education was 7 years, and median number
of children was 2 (Table 1). The median CD4+ T-cell count
before ART initiation was 276 cells per cubic millimeter
(interquartile range [IQR], 209–375 cells per cubic millimeter),
and the median HIV VL before ART initiation was 17,511
copies per milliliter (IQR, 2480–69,286 copies per milliliter).
Approximately 5% had a diagnosis of or had been treated for
tuberculosis at ART initiation (Table 1). The most common
ﬁrst-line ART regimens included zidovudine or stavudine or
tenofovir, lamivudine, and nevirapine or efavirenz.
Effect of Pregnancy in Response to ART
The 1041 women contributed 1196.1 person-years of
follow-up, with a median follow-up time of 1.0 year (IQR,
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0.6–1.7). One hundred ten women (10.6%) became pregnant
at least once after ART initiation. Women who became
pregnant were younger (median age, 29 vs. 33 years, P ,
0.001) and less likely to have any monthly income (41.8% vs.
52.1%, P = 0.04) than those who did not become pregnant
(Table 1). Overall, the proportion of women achieving viral
suppression was 82.9%; virologic failure occurred in 24.7%
of women, 5.9% progressed to WHO clinical stage III or IV,
and 1.2% died. Pregnancy was not associated with time to
viral suppression (adjusted hazard ratio, [aHR], 1.20, 95%
conﬁdence interval [CI]: 0.82 to 1.77), time to virologic
failure (aHR, 0.67, 95% CI: 0.37 to 1.22), time to WHO
clinical stage III or IV (aHR, 0.79, 95% CI: 0.19 to 3.30), or
time to death (aHR, 2.04, 95% CI: 0.25 to 16.8) (Table 2).
The median time to viral suppression for those who became
pregnant was 4.29 months compared with 4.26 months for
those who did not become pregnant. Incident pregnancy was
associated with an adjusted mean decrease in CD4+ T-cell
TABLE 1. Baseline Characteristics for 1041 HIV-Infected Women Included in the Analysis, by Pregnancy Status After Initiating ART
Characteristics at Study Enrollment
Overall, n = 1041
Pregnancy Recorded After
ART Initiation, n = 110
No Pregnancy Recorded After
ART Initiation, n = 931
N (%) N (%) N (%)
Study
Couples observational study 42 (4.0) 4 (3.6) 38 (4.1)
Partners in prevention 154 (14.8) 11 (10.0) 143 (15.4)
HSV/HIV transmission study
Partners PrEP study 845 (81.2) 95 (86.4) 750 (80.6)
Any monthly income 531 (51.0) 46 (41.8) 485 (52.1)
Married to study partner 996 (95.7) 105 (95.5) 891 (95.7)
Tuberculosis diagnosis or treatment* 54 (5.2) 4 (3.6) 50 (5.4)
WHO clinical stage III or IV* 157 (15.2) 16 (14.5) 141 (15.3)
Characteristics at Study Enrollment
Overall, n = 1041
Pregnancy Recorded After
ART Initiation, n = 110
No Pregnancy Recorded After
ART Initiation, n = 931
Median IQR Median IQR Median IQR
Age, yr 32 28–37 29 26–32 33 28–37
Years of education 7 5–9 8 5–9 7 4–9
Parity 2 1–4 2 1–4 2 1–4
Pre-ART CD4+ T-cell count/mm3 276 209–375 300 221–420 274 206–370
Pre-ART plasma HIV VL, copies/mL 17,511 2480–69,286 12,180 1997–54,381 18,071 2611–69,767
Follow-up time after ART initiation, yr† 1.0 0.6–1.7 1.7 1.0–2.2 0.9 0.5–1.6
*At time of ART initiation.
†Follow-up time included a VL measurement .6 months after ART initiation for 769 women (74%).
TABLE 2. Associations Between Incident Pregnancy and Clinical/Virologic Outcomes After Initiation of ART: The Couples
Observational Study, the Partners in Prevention Study, and the Partners PrEP Study
Outcome No. Participants No. Events Person-Years
Unadjusted Hazard
Ratio, 95% CI* aHR, 95% CI†
Time to plasma viral suppression 1041
Pregnant 28 16.6 1.07 (0.73 to 1.56) 1.16 (0.79 to 1.70)
Not pregnant 835 418.3 1.0 1.0
Time to virologic failure 769
Pregnant 12 50.4 0.87 (0.48 to 1.56) 0.67 (0.37 to 1.21)
Not pregnant 178 875.1 1.0 1.0
Time to WHO clinical stage III or IV 886
Pregnant 2 52.6 0.67 (0.16 to 2.78) 0.78 (0.19 to 3.26)
Not pregnant 50 908.4 1.0 1.0
Time to death 1041
Pregnant 1 66.8 1.53 (0.19 to 12.2) 2.02 (0.25 to 16.6)
Not pregnant 11 1129.3 1.0 1.0
*Analyses stratiﬁed by study.
†Adjusted for age, study year, pre-ART CD4+ count, pre-ART HIV VL, and tuberculosis diagnosis or treatment.
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count of 47.3 cells per cubic millimeter (P , 0.001), but not
with difference in HIV plasma VL (P = 0.06) (Tables 3 and
Fig. 1).
Because the studies did not have information about
attendance at clinical care visits outside the research clinics,
we used study retention as a proxy to evaluate overall
compliance with care. This was to see whether any differ-
ences by pregnancy status may be explained by differences in
follow-up, additional testing, and care of pregnant women
compared with nonpregnant women. There was no difference
in the odds of attendance at the next regular study visit
between pregnant and nonpregnant women (odds ratio, 0.79,
95% CI: 0.59 to 1.06).
DISCUSSION
In this analysis of prospective data from HIV-infected
women who initiated ART in 7 African countries, we found
that incident pregnancy after ART initiation was not associ-
ated with a delay in time to virologic suppression, increased
risk of virologic failure of therapy during follow-up, or
increased risk of clinical progression of HIV disease to WHO
clinical stage III or IV, or death. A modest decrease of CD4+
T-cell count was seen among those with incident pregnancies
(mean decrease of 47.7 cells per cubic millimeter compared
with nonpregnant women) over the course of follow-up.
Pregnancy-induced changes in the immune system may
increase susceptibility to and severity of infectious diseases.29
Although most evidence does not support a role for
pregnancy in accelerating HIV disease progression, mainly
from studies from the United States and Europe,2–4,7–15 some
data from developing countries have suggested progression of
HIV disease in pregnancy.5,6 Differences in the impact of
pregnancy on HIV disease across geographic areas may
reﬂect differences in other concomitant factors, such as
poverty, nutrition, concurrent infections, or stage of HIV
disease at the time of pregnancy.
Limited information is available about the effects of
pregnancy in response to ART. Physiologic changes during
pregnancy are multifaceted and may be compounded by the
introduction of ART. When a meta-analysis of studies on
pregnancy and HIV disease progression published through
2013 was stratiﬁed by ART availability, the pooled estimates
for the effect of pregnancy on accelerating progression to low
CD4+ T-cell count, HIV-related illness, AIDS-deﬁning illness,
and death were attenuated when ART was available, with
signiﬁcant effect modiﬁcation by ART availability on the
effects of pregnancy on AIDS-deﬁning illness and death.1 For
most of these studies, ART, if available, was initiated during
pregnancy. Data on the effect of incident pregnancy among
women already taking ART are even more limited. It is
however important to make this distinction, as women who
initiate ART during pregnancy do so mainly for prevention of
mother-to-child transmission and are more likely to be
healthier, whereas women who are on ART when they become
pregnant are more likely to have initiated ART for their own
immunologic or clinical indications. In a single study with the
TABLE 3. Associations Between Incident Pregnancy and CD4+ T-Cell Count and Plasma HIV VL After Initiation of ART: The
Couples Observational Study, the Partners in Prevention Study, and the Partners PrEP Study
Outcome No. Participants Median IQR Mean Difference* P
CD4+ T-cell count/mm3 1035
Pregnant 436.5 325.5–593.0 247.3 ,0.001
Not pregnant 418.0 312.0–570.0
Plasma HIV VL, log 10 copies/mL 1041
Pregnant 40 40–120 20.13 0.07
Not pregnant 40 40–136
*From longitudinal mixed-effects model with log10 VL and CD4+ counts as the outcome in separate models. Analyses adjusted for study, time since ART initiation, age, study
year, pre-ART CD4+ count, pre-ART HIV VL, and tuberculosis diagnosis or treatment (since the latter may affect ART pharmacokinetics and therefore potentially effectiveness).
FIGURE 1. CD4+ T-cell count (A) and Plasma HIV VL (B) from
initiation of ART by time-varying incident pregnancy.
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primary aim of evaluating incident pregnancy on clinical HIV
disease progression among HIV-infected women who became
pregnant in South Africa, incident pregnancy after ART
initiation was not associated with an increased hazard of
a new AIDS event or death.30
Unlike our study’s ﬁndings of no effect of incident
pregnancy on virologic failure, a study of 541 pregnancies
during follow-up of 5954 women in South Africa found
incident pregnancy after combination ART initiation was
associated with a modest increase in risk of virologic failure
(aHR, 1.34, 95% CI: 1.02 to 1.78).18 That study’s strength was
its large sample size and careful statistical analysis; however, it
was based on analysis of observational data from a single
clinic’s database that lacked baseline HIV VL for most women,
and confounding cannot be ruled out. In 3 much smaller studies,
there was no evidence of an effect of incident pregnancy on
HIV RNA change or virologic failure.19–21 The largest of these
studies was among 128 women who became pregnant after 3 or
more months of combination ART in the Swiss Mother and
Child HIV Cohort Study, which found no difference in the
frequency of virologic failure during pregnancy compared with
a period of equal duration before and after pregnancy (adjusted
odds ratio = 1.04, 95% CI:0.48 to 2.28).20
Our ﬁnding of a modest decrease of the CD4+ T-cell
count among women with incident pregnancies (mean
decrease of 47.7 cells per cubic millimeter) was not
unexpected. Cellular immunity and CD4+ lymphocyte levels
are expected to decline during pregnancy in all women but
eventually return to prepregnancy levels.31 In a pooled
analysis of 4 studies,3,9,11,12 HIV-infected pregnant women
exposed to no or partial ART had marginally increased risk
(1.41, 95% CI: 0.99 to 2.02) of progressing to a low CD4+
T-cell count compared with nonpregnant HIV-infected
women.1 Although these studies counted the postpartum period
in the pregnancy person-time, other studies have compared
the prepregnancy, pregnancy, and postpartum periods and
found that CD4+ T-cell count declines during pregnancy are
temporary effects, likely due to physiologic effects of
pregnancy, and rebound in the postpartum period.15,19
Our analysis has some limitations. The follow-up time
was not long enough to allow separate evaluation of
pregnancy versus any postpartum effects. As most of the
women were on a standard ﬁrst-line ART regimen, we were
also unable to examine possible effects of pregnancy in
response to different ART regimens. Despite our relatively
large sample size, the power of this study to detect small
effects of pregnancy in response to ART may be limited.
Strengths of our study include the prospective, systematic,
and detailed data collection across all clinical study partic-
ipants, statistical analysis to account for time-varying varia-
bles, and recruitment from several countries in Africa, which
may enhance generalizability of the results.
Rapid adoption of the WHO’s recommendation of
lifelong ART for all pregnant and breastfeeding women
living with HIV regardless of CD4+ T-cell count or clinical
stage of disease has led to large increases in the proportion of
HIV-infected pregnant women using and seeking ART.
Moreover, with the recommendation of maintaining ART
for life and the low risk of HIV transmission to their infants
when HIV viremia is suppressed, more women will remain
healthy and experience repeat incident pregnancies while
using ART. Indeed, emerging data suggest that use of ART is
associated with heightened feelings of hope, health, fertility
desires, and a 70% higher rate of subsequent pregnancy.32–35
It is thus important to understand how pregnancy may affect
a woman’s response to ART. Our ﬁndings add to the
emerging body of evidence that incident pregnancy does
not seem to affect virologic, immunologic, and clinical
response to ART. These ﬁndings have implications for
counseling HIV-infected women of reproductive age who
desire pregnancy about the potential for a healthy pregnancy
and child when ART is used. However, intensive counseling
about the importance of antenatal and postnatal adherence to
ART for the mothers’ and infant’s health and continued
careful monitoring of long-term clinical outcomes for both
women and their infants is important.
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